Browse by Poster Presenter

Type here to filter the list

B
Babichev, Yael

Lunenfeld Tanenbaum Research Institute
(P 05) GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
Yael Babichev
Favorite
(P 124) EFFECT OF MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND AND CHEMOTHERAPY ON THE IMMUNE PROFILE OF A MURINE MODEL OF RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Yael Babichev
Favorite
(P 190) SELECTIVELY TARGETING THE EPIGENOME IN EMBRYONAL RHABDOMYOSARCOMA
Yael Babichev
Favorite
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Yael Babichev
Favorite
Baek, Rikke

Department of Clinical Immunology, Aalborg University Hospital
(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Rikke Baek
Favorite
Baek, Wooyeol

Yonsei University College of Medicine
(P 265) DEVELOPMENT OF THERAPEUTIC STRATEGY FOR DESMOID TUMOR WITH NOVEL PATIENT-DERIVED PRECLINICAL MODEL
Wooyeol Baek
Favorite
Bagué, Sílvia

Hospital de la Santa Creu i Sant Pau
(P 135) PREDICTIVE VALUE OF ISG15 AND PPAP2B IN SOLITARY FIBROUS TUMOR TREATED WITH SUNITINIB AND NIVOLUMAB: A CORRELATIVE STUDY FROM IMMUNOSARC, A SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS) PHASE II TRIAL
Sílvia Bagué
Favorite
BAHLEDA, RASTILAV

INSTITUT GUSTAVE ROUSSY
(P 217) PLANNED MARGINAL (R1) RESECTION IN PRIMARY RETROPERITONEAL SARCOMAS: RETROSPECTIVE SERIES ON 168 PATIENTS FROM A NATIONAL SPECIALIZED REFERRAL CENTER
RASTILAV BAHLEDA
Favorite
Bailey, Barbara

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Barbara Bailey
Favorite
Bailey, Kelly

Department of Pediatrics, University of Pittsburgh
(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Kelly Bailey
Favorite
Bailey, Nathanael

Department of Pathology, University of Pittsburgh
(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Nathanael Bailey
Favorite
Bailey, Swneke

Department of Cardiothoracic Surgery, McGill University
(P 232) DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA
Swneke Bailey
Favorite
Bajic, Andrea

Department of Human Genetics, McGill University
(P 022) EZHIP ECTOPIC EXPRESSION AND ITS ROLE IN OSTEOSARCOMA PATHOGENESIS
Andrea Bajic
Favorite
Bajpai, Jyoti

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Jyoti Bajpai
Favorite
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Jyoti Bajpai
Favorite
Bakker, Pauline

LUMC
(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL
Pauline Bakker
Favorite
Balaguer Román, Andrés

Hospital Universitario Virgen de la Arrixaca
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Andrés Balaguer Román
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Andrés Balaguer Román
Favorite
Balaguer Roman, Andres

“La Arrixaca” Clinical University Hospital
(P 055) PROGNOSTIC VALUE AND USEFULNESS OF HAEMATOLOGICAL BIOMARKERS IN LIPOSARCOMAS.
Andres Balaguer Roman
Favorite
(P 078) GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Andres Balaguer Roman
Favorite
Baldaccini, Davide

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Davide Baldaccini
Favorite
Baldaccini, Davide

Humanitas Research Hospital
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Davide Baldaccini
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Davide Baldaccini
Favorite
Baldi, Giacomo

Department of Medical Oncology, Hospital of Prato
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Giacomo Baldi
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Giacomo Baldi
Favorite
Baldini, Elizabeth

Dana-Farber Cancer Institute
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Elizabeth Baldini
Favorite
Ballesteros, Pablo

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Pablo Ballesteros
Favorite
Balzarini, Luca

Department of Radiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Luca Balzarini
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Luca Balzarini
Favorite
Banavali, Shripad

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Shripad Banavali
Favorite
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Shripad Banavali
Favorite
Banuelos, Ailani

Waubonsie Valley High School
(P 032) PLEURAL RELAPSE OF OSTEOSARCOMA AFTER TALC PLEURODESIS
Ailani Banuelos
Favorite
Barghi, Farinaz

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Farinaz Barghi
Favorite
Barisella, Marta

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Marta Barisella
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Marta Barisella
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Marta Barisella
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Marta Barisella
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Marta Barisella
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Marta Barisella
Favorite
Barnett, Marie

Memorial Sloan Kettering Cancer Center
(P 04) EXPERT PANEL REVIEW OF THE PRO-AYA: PARTIENT-REPORTED OUTCOMES FOR ADOLESCENTS AND YOUNG ADULTS WITH CANCER
Marie Barnett
Favorite
Barreto Coelho, Priscila

Sylvester Comprehensive Cancer Center
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Priscila Barreto Coelho
Favorite
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Priscila Barreto Coelho
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Priscila Barreto Coelho
Favorite
Barreto-Coelho, Priscila

University of Miami/Sylvester Comprehensive Cancer Center
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Priscila Barreto-Coelho
Favorite
Barretta, Francesco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Francesco Barretta
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Francesco Barretta
Favorite
Barry, Janie

CIUSSS de l'Est-de-l'Île-de-Montréal
(P 054) PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Janie Barry
Favorite
(P 308) REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Janie Barry
Favorite
Barthoulot, Mael

Centre Oscar Lambret
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Mael Barthoulot
Favorite
Basile, Georges

CIUSSS de l'Est-de-l'Île-de-Montréal
(P 054) PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Georges Basile
Favorite
(P 308) REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Georges Basile
Favorite
Basso, Umberto

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Umberto Basso
Favorite
Basu Mallick, Atrayee

Sidney Kimmel Cancer Center, Thomas Jefferson University
(P 095) A COLLABORATIVE MULTIDISCIPLINARY APPROACH MAY LEAD TO ENHANCED CLINICAL OUTCOMES AND QUALITY OF CARE FOR PATIENTS WITH DIFFUSE TGCT
Atrayee Basu Mallick
Favorite
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Atrayee Basu Mallick
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Atrayee Basu Mallick
Favorite
Batruk, Hubert

Medical University of Warsaw
(P 169) WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS
Hubert Batruk
Favorite
Batus, Marta

Rush University Medical Center
(P 053) PET-CT STAGING AFFECTS TIME TO TREATMENT IN SARCOMA
Marta Batus
Favorite
(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?
Marta Batus
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Marta Batus
Favorite
BAUCHET, Luc

CHU MONTPELLIER
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Luc BAUCHET
Favorite
Bauer, Henrik

Musculoskeletal Tumor Service, Karolinska University Hospital, Stockholm, Sweden
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Henrik Bauer
Favorite
Bauer, Sebastian

Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Sebastian Bauer
Favorite
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Sebastian Bauer
Favorite
(P 121) USING IN VITRO MODELS TO PREDICT IMATINIB RESPONSES IN PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR
Sebastian Bauer
Favorite
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Sebastian Bauer
Favorite
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Sebastian Bauer
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Sebastian Bauer
Favorite
Baum, Christian

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Christian Baum
Favorite
Baumgarten, Christina

sos-desmoid e.V.; German Sarcoma Foundation; Sarcoma Patients Advocacy Global Network (SPAGN)
(P 264) DESMOID AND TRAUMA: REAL INCIDENCE AND MEDICOLEGAL ASPECTS OF CAUSALITY
Christina Baumgarten
Favorite
Baumgartner, Julia

Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Julia Baumgartner
Favorite
Baumhoer, Daniel

University Hospital Basel
(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Daniel Baumhoer
Favorite
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Daniel Baumhoer
Favorite
Bautista, Francisco

Hospital del Niño Jesús
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Francisco Bautista
Favorite
Bayer, Kevin

Inhibrx, Inc
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Kevin Bayer
Favorite
Bayer, Paige

Adaptimmune
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Paige Bayer
Favorite
Bazzurri, Serena

Department of Medical Oncology, Hospital of Prato, Prato, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Serena Bazzurri
Favorite
Bear, Jonathan

Naval Medical Center
(P 282) FUNGATING SOFT TISSUE SARCOMA: A COMPLEX TREATMENT DILEMMA
Jonathan Bear
Favorite
Beasley, Gary

University of Iowa Stead Family Children's Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Gary Beasley
Favorite
Bedeschi Rego De Mattos, Camila

Skåne University Hospital
(P 242) LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Camila Bedeschi Rego De Mattos
Favorite
Beeravally Nagulapally, Abhinav

Atrium Health - Levine Children's Hospital
(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Abhinav Beeravally Nagulapally
Favorite
Bektas, Meryem

RTI Health Solutions
(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS
Meryem Bektas
Favorite
Belanger, Bruno

Bcomtesting Inc.
(P 288) LOCKING PLATE AUGMENTATION OF POLYMETHYLMETHACRYLATE-FILLED DISTAL FEMUR DEFECTS
Bruno Belanger
Favorite
Belayneh, Rebekah

University of Pittsburgh Medical Center
(P 025) INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Rebekah Belayneh
Favorite
Bell, Timothy

SpringWorks Therapeutics
(P 260) BURDEN OF ILLNESS OF DESMOID TUMORS
Timothy Bell
Favorite
Beltran Guerra, Isabel

Hospital Universitario Virgen de Valme
(P 267) EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.
Isabel Beltran Guerra
Favorite
Belzarena, Ana

University of Missouri
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Ana Belzarena
Favorite
(P 280) COMPLEX SHOULDER EXTRA-ARTICULAR RESECTION AND RECONSTRUCTION: A NOVEL DESIGN
Ana Belzarena
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Ana Belzarena
Favorite
Ben Ami, Eytan
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Eytan Ben Ami
Favorite
Benedetti Pedroza, Johana

Hospital Universitario Virgen del Rocío
(P 267) EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.
Johana Benedetti Pedroza
Favorite
Benelli, Matteo

Bioinformatics Unit, Hospital of Prato, Prato, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Matteo Benelli
Favorite
Benoit-perejón, Jonatan Zacarías

Hospital Universitario de Jaén
(P 083) PERFORMANCE OF THE MESENCHYMAL TUMOR COMMITTEE IN A SMALL HOSPITAL IN SOUTHERN SPAIN
Jonatan Zacarías Benoit-perejón
Favorite
Benson, Charlotte

The Royal Marsden NHS Foundation Trust
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Charlotte Benson
Favorite
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Charlotte Benson
Favorite
Bergamaschi, Laura

Unit of Immunotherapy of Human Tumors, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 179) IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Laura Bergamaschi
Favorite
Bergovec, Marko

Department of Orthopaedics and Trauma, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Marko Bergovec
Favorite
Bernthal, Nicholas

David Geffen School of Medicine at UCLA, Santa Monica, CA, USA
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Nicholas Bernthal
Favorite
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Nicholas Bernthal
Favorite
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Nicholas Bernthal
Favorite
(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Nicholas Bernthal
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Nicholas Bernthal
Favorite
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Nicholas Bernthal
Favorite
(P 286) INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Nicholas Bernthal
Favorite
Berry, Daniel

Mayo Clinic
(P 302) SERUM METAL ION CONCENTRATIONS IN THE SETTING OF AN ONCOLOGIC ENDOPROSTHESIS: IS THERE CAUSE FOR CONCERN?
Daniel Berry
Favorite
Bertagnolli, Monica

Brigham and Women’s Hospital
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Monica Bertagnolli
Favorite
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Monica Bertagnolli
Favorite
Berthiaume, Marie-Josee

CIUSSS de l'Est-de-l'Île-de-Montréal
(P 308) REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Marie-Josee Berthiaume
Favorite
Bertulli, Rossella

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Rossella Bertulli
Favorite
(P 203) MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Rossella Bertulli
Favorite
Bertuzzi, Alexia

Humanitas Research Hospital
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Alexia Bertuzzi
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Alexia Bertuzzi
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Alexia Bertuzzi
Favorite
Bertuzzi, Alexia Francesca

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Alexia Francesca Bertuzzi
Favorite
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Alexia Francesca Bertuzzi
Favorite
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Alexia Francesca Bertuzzi
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Alexia Francesca Bertuzzi
Favorite
Berz, David

Valkyrie Clinical Trials
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
David Berz
Favorite
Betel, Doron

Weill Cornell Medicine Graduate School of Medical Sciences
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Doron Betel
Favorite
Bhadri, Vivek

Chris O'Brien Lifehouse
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Vivek Bhadri
Favorite
(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC
Vivek Bhadri
Favorite
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Vivek Bhadri
Favorite
Bhargava, Prabhat

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Prabhat Bhargava
Favorite
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Prabhat Bhargava
Favorite
Bhogal, Sumail

University of Pittsburgh Medical Center
(P 025) INCREASED ALDH1A1 AND ATOX1 GENE EXPRESSION AND COPPER LEVELS IN CANINE OSTEOSARCOMA PATIENTS
Sumail Bhogal
Favorite
(P 046) EVALUATION OF INTRAOPERATIVE TUMOR MARGINS IN SARCOMA WITH FLUORESCENT DYE IMAGING: A PRELIMINARY ANALYSIS OF RESULTS
Sumail Bhogal
Favorite
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Sumail Bhogal
Favorite
Bhura, Zainab

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto; The Hospital for Sick Children, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre, Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Zainab Bhura
Favorite
Bialick, Steven

University of Miami/Sylvester Comprehensive Cancer Center
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Steven Bialick
Favorite
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Steven Bialick
Favorite
(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA
Steven Bialick
Favorite
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Steven Bialick
Favorite
Bianchi, Giuseppe

Department of Orthopedic Oncology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Giuseppe Bianchi
Favorite
Bianchi, Gottardo

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Gottardo Bianchi
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Gottardo Bianchi
Favorite
Biegel, Jaclyn

Children's Hospital Los Angeles
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Jaclyn Biegel
Favorite
Bijangi-Vishehsaraei, Khadijeh

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Khadijeh Bijangi-Vishehsaraei
Favorite
Bindra, Ranjit

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Ranjit Bindra
Favorite
Binitie, Odion

Moffitt Cancer Center
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Odion Binitie
Favorite
(P 305) THE INCIDENCE OF THROMBOEMBOLIC EVENTS DURING HOSPITALIZATIONS FOLLOWING SURGICAL RESECTION OF LOWER EXTREMITY SARCOMAS IN CHILDREN: UTILIZING THE PEDIATRIC HEALTH INFORMATION SYSTEM (PHIS) DATABASE
Odion Binitie
Favorite
Biondi, Nicola

Precision Sarcoma Research Group, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Nicola Biondi
Favorite
Bird, Justin

University of Texas MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Justin Bird
Favorite
Birlingmair, Jacob

University of Kansas Medical Center
(P 276) ASSOCIATION OF THE COVID-19 PANDEMIC WITH SOFT TISSUE SARCOMA CHARACTERISTICS
Jacob Birlingmair
Favorite
Bishop, Andrew

MD Anderson Cancer Center
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Andrew Bishop
Favorite
Bishop, Michael

St. Jude Children's Research Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Michael Bishop
Favorite
Biswas, Swethajit

Adaptimmune
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Swethajit Biswas
Favorite
Blair, Helen

Translational and Clinical Research Institute, Newcastle University and Wolfson Childhood Cancer Research Centre, Newcastle upon Tyne, UK
(P 172) DEVELOPMENT OF A TARGETED DUAL-MODALITY RADIOIMMUNOCONJUGATE FOR IMAGE GUIDED SARCOMA SURGERY
Helen Blair
Favorite
Blanco, Gerardo

Hospital universitario badajoz
(P 119) SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Gerardo Blanco
Favorite
Blank, Alan

Rush University Medical Center
(P 053) PET-CT STAGING AFFECTS TIME TO TREATMENT IN SARCOMA
Alan Blank
Favorite
(P 062) WHAT IS THE CLINICAL IMPACT OF STAGING AND SURVEILLANCE PET-CT SCAN FINDINGS IN PATIENTS WITH BONE AND SOFT TISSUE SARCOMA?
Alan Blank
Favorite
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Alan Blank
Favorite
(P 086) RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Alan Blank
Favorite
(P 094) TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS IS UNCOMMON AFTER INTRALESIONAL CURETTAGE IN GIANT CELL TUMOR OF BONE
Alan Blank
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Alan Blank
Favorite
(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Alan Blank
Favorite
(P 273) 3D-PRINTED PATIENT-SPECIFIC CUTTING GUIDES VERSUS FREEHAND RESECTION FOR INTERNAL HEMIPELVECTOMY: CLINICAL AND ONCOLOGIC OUTCOMES
Alan Blank
Favorite
(P 277) BEARING SELECTION IN PROXIMAL FEMORAL REPLACEMENT: A COMPARISON OF CLINICAL OUTCOMES
Alan Blank
Favorite
(P 283) HIP ARTHROPLASTY OUTCOMES IN METASTATIC BONE DISEASE
Alan Blank
Favorite
(P 287) INTERNAL HEMIPELVECTOMY: A SINGLE INSTITUTION'S LEARNING CURVE AND LONGITUDINAL EXPERIENCE
Alan Blank
Favorite
(P 294) PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Alan Blank
Favorite
(P 295) PERIACETABULAR INTERNAL HEMIPELVECTOMY WITH AND WITHOUT SACRAL RESECTION: AN INSTITUTIONAL EXPERIENCE AND SYSTEMATIC REVIEW
Alan Blank
Favorite
Blay, Jean-Yves

Centre Léon Bérard and Université Claude Bernard, Lyon, France
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Jean-Yves Blay
Favorite
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Jean-Yves Blay
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Jean-Yves Blay
Favorite
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Jean-Yves Blay
Favorite
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Jean-Yves Blay
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Jean-Yves Blay
Favorite
Blazer, Dan

Duke University Medical Center
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Dan Blazer
Favorite
Block, Matthew

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Matthew Block
Favorite
Blouch, Kristin

Director, Disease Strategy Oncology, GSK
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Kristin Blouch
Favorite
Blumenschein, George

The University of Texas MD Anderson Cancer Center
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
George Blumenschein
Favorite
Bock, Daena

Eisai Inc.
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Daena Bock
Favorite
Boffano, Michele

Orthopedic Oncologic Reconstructive Surgery, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Michele Boffano
Favorite
Boglione, Antonella

Oncology Department, ASL Città di Torino
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Antonella Boglione
Favorite
Bokhyan, Beniamin

Federal State Budgetary Institution «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO)
(P 158) NEOADJUVANT COMBINATION OF DOXORUBICIN, CISPLATIN AND METHOTREXATE IN PATIENTS AGED 24-40 YEARS WITH OSTEOSARCOMA UNDER THE COVERAGE OF HEMODIALYSIS. AMAP2021-7-2. ONGOING TRIAL
Beniamin Bokhyan
Favorite
Bollard, Julien

Research and Innovation, Centre Léon Bérard
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Julien Bollard
Favorite
Bolshinsky, Maital

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Maital Bolshinsky
Favorite
Bompas, Emmanuelle

Department of Medicine, Institut Cancerologie de l'Ouest
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Emmanuelle Bompas
Favorite
Bonenkamp, Han

Radboud University Medical Center
(P 272) PREGNANCY-ASSOCIATED DESMOID FIBROMATOSIS: A DUTCH MULTI-CENTRE RETROSPECTIVE ANALYSIS
Han Bonenkamp
Favorite
Bongiovanni, Alberto

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Alberto Bongiovanni
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Alberto Bongiovanni
Favorite
Boone, Mathieu

CHU AMIENS
(P 080) INTRACRANIAL SOLITARY FIBROUS TUMOUR/HEMANGIOPERICYTOMA MANAGEMENT: A FRENCH MULTICENTRE RETROSPECTIVE STUDY
Mathieu Boone
Favorite
Borchert, Sabrina

Institute of Pathology, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Sabrina Borchert
Favorite
Borinstein, Scott

Vanderbilt University Medical Center
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Scott Borinstein
Favorite
(P 266) EFFICACY OF LIPOSOMAL DOXORUBICIN IN PATIENTS WITH INTRA- AND EXTRA-ABDOMINAL DESMOID FIBROMATOSIS
Scott Borinstein
Favorite
Bouberhan, Sara

Massachusetts General Hospital/Harvard Medical School
(P 143) A PHASE 1 B LEAD-IN TO A RANDOMIZED PHASE 2 TRIAL OF LURBINECTEDIN PLUS DOXORUBICIN IN LEIOMYOSARCOMA (LMS): RESULTS FROM THE PHASE 1B SOFT-TISSUE SARCOMA (STS) LEAD-IN
Sara Bouberhan
Favorite
Bouchard-Fortier, Antoine

University of Calgary
(P 205) PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Antoine Bouchard-Fortier
Favorite
Bouchard-Fortier, Antoine

Department of Surgery, Foothills Medical Centre
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Antoine Bouchard-Fortier
Favorite
Bouhamama, Amine

CENTRE LEON BERARD
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Amine Bouhamama
Favorite
Boukovinas, Ioannis

Biokliniki
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Ioannis Boukovinas
Favorite
Boulanger-Gobeil, Cindy

Centre Hospitalier Universitaire de Québec / Université Laval
(P 088) RETHINKING THE MANAGEMENT OF AGGRESSIVE ANGIOMYXOMA: A REPORT FROM FOUR CANADIAN SARCOMA CENTRES.
Cindy Boulanger-Gobeil
Favorite
Bourque, Melissa

St. Jude Children's Research Hospital
(P 012) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Melissa Bourque
Favorite
Boux, Elena

Orthopedic Oncologic Reconstructive Surgery, CTO Hospital, AOU Città della Salute e della Scienza di Torino
(P 058) SARCOPENIA AS A NEGATIVE PROGNOSTIC FACTOR IN LOCALIZED EXTREMITIES/TRUNK WALL SOFT TISSUE SARCOMAS
Elena Boux
Favorite
Bovee, J.V.M.G.

Department of Pathology, Leiden University Medical Center
(P 109) NOVEL CANDIDATE BIOMARKERS FOR FLUORESCENCE IMAGE-GUIDED SURGERY IN GASTROINTESTINAL STROMAL TUMORS
J.V.M.G. Bovee
Favorite
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
J.V.M.G. Bovee
Favorite
(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL
J.V.M.G. Bovee
Favorite
(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
J.V.M.G. Bovee
Favorite
Boye, Kjetil

Oslo University Hospital
(P 114) PROGNOSTIC IMPACT OF CIRCULATING TUMOR DNA DETECTION IN FIRST-LINE TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR
Kjetil Boye
Favorite
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Kjetil Boye
Favorite
Boyle, Richard

Royal Prince Alfred Hospital
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Richard Boyle
Favorite
Brackert, Sandra

UCLA
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Sandra Brackert
Favorite
Brahmi, Mehdi

Department of Medical Oncology, Centre Léon Bérard,
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Mehdi Brahmi
Favorite
(P 189) PROGNOSTIC IMPACT OF NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA-1 EXPRESSION AND HUMAN LEUKOCYTE ANTIGEN SUBTYPES IN METASTATIC SYNOVIAL SARCOMA
Mehdi Brahmi
Favorite
(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.
Mehdi Brahmi
Favorite
Braire-deBruijn, Inge

Department of Pathology, Leiden University Medical Center, Leiden
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Inge Braire-deBruijn
Favorite
Brar, Savtaj

Department of Surgery, Mount Sinai Hospital; Department of Surgery, University of Toronto
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Savtaj Brar
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Savtaj Brar
Favorite
Brcic, Iva

Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Iva Brcic
Favorite
Breen, William

Mayo Clinic
(P 201) LOCAL CONTROL AND SURVIVAL OUTCOMES IN PEDIATRIC NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA: THE MAYO CLINIC EXPERIENCE
William Breen
Favorite
Bresler, Scott

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Scott Bresler
Favorite
Brewer, Jerry

Mayo Clinic (Rochester)
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Jerry Brewer
Favorite
Brichard, Benedicte

Cliniques Universitaires Saint Luc, Department of Pediatric Haematology and Oncology, Université Catholique de Louvain
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Benedicte Brichard
Favorite
Brich, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Silvia Brich
Favorite
Brigham, Don

Sarcoma Oncology Center
(P 122) AN UPDATE ON TNT: A PHASE-2 STUDY OF THE EFFICACY AND SAFETY OF TALIMOGENE LAHERPAREPVEC, NIVOLUMAB, AND TRABECTEDIN IN ADVANCED SARCOMA
Don Brigham
Favorite
(P 123) COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Don Brigham
Favorite
(P 126) GALLANT: A PHASE 2 STUDY USING METRONOMIC GEMCITABINE, DOXORUBICIN, NIVOLUMAB, AND DOCETAXEL AS SECOND/THIRD-LINE THERAPY FOR ADVANCED SARCOMA (NCT04535713)
Don Brigham
Favorite
(P 132) PHASE 1/2 COMBINATION REGIMEN WITH IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE THERAPY FOR ADVANCED LEIOMYOSARCOMA [NCT03138161]
Don Brigham
Favorite
(P 133) PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Don Brigham
Favorite
(P 137) SAINT: FIVE YEAR RESULTS OF A PHASE 2 TRIAL USING IPILIMUMAB (I), NIVOLUMAB (N) AND TRABECTEDIN (T) FOR PREVIOUSLY UNTREATED ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
Don Brigham
Favorite
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Don Brigham
Favorite
Brigman, Brian

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Brian Brigman
Favorite
(P 288) LOCKING PLATE AUGMENTATION OF POLYMETHYLMETHACRYLATE-FILLED DISTAL FEMUR DEFECTS
Brian Brigman
Favorite
Brinch, Charlotte

Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital
(P 120) THE DIAGNOSTIC AND PROGNOSTIC VALUE OF PLASMA SMALL EXTRACELLULAR VESICLES PHENOTYPE IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR
Charlotte Brinch
Favorite
Brito Accurso, Ariadna

Cancer Research Center Toulouse
(P 253) THE IMPACT OF CELL FUSION IN LEIOMYOSARCOMA ONCOGENESIS
Ariadna Brito Accurso
Favorite
Britschgi, Christian

University Hospital Zürich, University of Zürich, Comprehensive Cancer Center Zürich
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Christian Britschgi
Favorite
Brockstein, Bruce

NorthShore University HealthSystem
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Bruce Brockstein
Favorite
Broida, Samuel

Mayo Clinic (Rochester)
(P 278) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Samuel Broida
Favorite
(P 289) MERKEL CELL CARCINOMA OF UNKNOWN PRIMARY: CLINICAL PRESENTATION AND OUTCOMES
Samuel Broida
Favorite
(P 291) OUTCOME OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE UPPER EXTREMITY
Samuel Broida
Favorite
(P 293) OUTCOMES OF MULTIDISCIPLINARY TREATMENT OF MERKEL CELL CARCINOMA OF THE LOWER EXTREMITY
Samuel Broida
Favorite
(P 296) PET IMAGING VERSUS CLINICAL EXAMINATION IN DETERMINING LYMPH NODE INVOLVEMENT IN MERKEL CELL CARCINOMA OF THE EXTREMITY
Samuel Broida
Favorite
Brophy, Francine

Adaptimmune
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Francine Brophy
Favorite
Brosjö, Otte

Karolinska University Hospital
(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Otte Brosjö
Favorite
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Otte Brosjö
Favorite
Brotea-Mosoiu, Silvia

Oncology Institute of Bucharest
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Silvia Brotea-Mosoiu
Favorite
Brown, Anthony

Radiology Imaging Associates
(P 294) PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Anthony Brown
Favorite
Brown, Dale

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Dale Brown
Favorite
Brown, Danielle

University of California, Los Angeles
(P 286) INDICATIONS AND LONGEVITY OF ENDOPROSTHETIC RECONSTRUCTIONS FOR PATIENTS WITH METASTATIC BONE DISEASE
Danielle Brown
Favorite
Brown, Jeffrey

Huntsman Cancer Institute
(P 306) THERMAL NECROSIS IN ORTHOPAEDIC BONE TUMORS
Jeffrey Brown
Favorite
Brown, Joel

Moffitt
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Joel Brown
Favorite
Bruckheimer, Elchanan
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Elchanan Bruckheimer
Favorite
Bruland, Øyvind

Oslo University Hospital
(P 115) PSYCHOLOGICAL AND SOCIAL CHALLENGES OF PATIENTS WITH ADVANCED AND METASTATIC GASTROINTESTINAL STROMAL TUMORS ON LONG-TERM TREATMENT WITH TYROSINE KINASE INHIBITORS: A QUALITATIVE STUDY
Øyvind Bruland
Favorite
Brunello, Antonella

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Antonella Brunello
Favorite
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Antonella Brunello
Favorite
Buac, Neil

Rush University Medical Center
(P 081) MISSING DATA IN THE DEVELOPMENT AND EXTERNAL VALIDATION OF MACHINE LEARNING MODELS FOR SURVIVAL PREDICTION IN SARCOMA
Neil Buac
Favorite
(P 094) TOTAL KNEE ARTHROPLASTY FOR OSTEOARTHRITIS IS UNCOMMON AFTER INTRALESIONAL CURETTAGE IN GIANT CELL TUMOR OF BONE
Neil Buac
Favorite
(P 206) RADIOTHERAPY LEADS TO IMPROVED OVERALL SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Neil Buac
Favorite
Budak, Gungor

Seven Bridges
(P 244) MUTATIONAL BURDEN OF COPY NUMBER VARIANTS VS STRUCTURAL VARIANTS IN EXTRASKELETAL MYXOID CHONDROSARCOMA: A CASE STUDY
Gungor Budak
Favorite
Bui, Nam

Stanford University
(P 047) FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Nam Bui
Favorite
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Nam Bui
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Nam Bui
Favorite
Bunce, Catey

The Royal Marsden NHS Foundation Trust
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Catey Bunce
Favorite
Burgoyne, Adam

UC San Diego Moores Cancer Center
(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Adam Burgoyne
Favorite
Burke, Zachary

University of Toronto
(P 059) SURGICAL MANAGEMENT OF CHONDROSARCOMA OF LONG BONES UTILIZING A PRE-OPERATIVE RADIOLOGIC AGGRESSIVENESS SCORE?
Zachary Burke
Favorite
(P 284) HOW DO THE OUTCOMES OF RADIATION ASSOCIATED PELVIC AND SACRAL BONE SARCOMAS COMPARE TO PRIMARY OSTEOSARCOMAS FOLLOWING SURGICAL RESECTION?
Zachary Burke
Favorite
(P 304) SURGICAL STAGING OF OSTEOSARCOMA: WHAT IS THE OPTIMAL METHOD FOR PREDICTING LOCAL RECURRENCE?
Zachary Burke
Favorite
Bush, Jonathan

BC Children's Hospital, University of British Columbia
(P 033) REDUCED H3K27ME3 IMMUNOEXPRESSION IN PEDIATRIC OSTEOSARCOMA IS ASSOCIATED WITH POOR RESPONSE TO NEOADJUVENT THERAPY
Jonathan Bush
Favorite
Butler, Marcus

Princess Margaret Cancer Centre
(P 127) IDENTIFYING MAGE-A4-POSITIVE TUMORS FOR SPEAR T-CELL THERAPIES IN HLA-A*02-ELIGIBLE PATIENTS
Marcus Butler
Favorite
Buxton, Allen

Children's Oncology Group
(P 023) FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Allen Buxton
Favorite
Buzzaccarini, Maria

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Maria Buzzaccarini
Favorite
Byrum, Andrea

Nationwide Children's Hospital
(P 229) CHARACTERIZING THE MICROSATELLITE-BINDING FUNCTION OF EWS-FLI AND ETV6 IN EWING SARCOMA
Andrea Byrum
Favorite